Clinical trial NCT04648410: Corticosteroids in Severe COVID-19(ASAP-C Study)
Official title: Administration of Systemic Corticosteroids Among Critically Ill Patients With COVID-19: Electronic Survey (ASAP-C Study)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Severe COVID-19
Lead sponsor: Brno University Hospital
Sponsor class: OTHER
First posted: 2020-12-01
Enrollment: 2000
Sex: ALL
Minimum age (years): 28
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Members of European Society of Intensive Care

Brief summary: Administration of systemic corticosteroids for patients with severe forms of severe acute respiratory syndrome(SARS-Co-2) infection are recommended by several guidelines. In the very beginning of SARS-Co-2 pandemic the early recommendation by professional organization was against routine use of corticosteroids for patients with coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS), despite previous data and clinical practice for patients with refractory or severe form of ARDS.

Detailed description: Administration of systemic corticosteroids for patients with severe forms of SARS-Co-2 infection are recommended by several guidelines. In the very beginning of SARS-Co-2 pandemic the early recommendation by professional organization was against routine use of corticosteroids for patients with coronavirus disease 2019 (COVID-19) ARDS, despite previous data and clinical practice for patients with refractory or severe form of ARDS. But at the latest after publication of RECOVERY trial (Randomized Evaluation of Covid-19 Therapy, July 2020) and ensued metaanalysis of World Health Organization (WHO) working group, the routine administration of systemic corticosteroids was revisited. However, there are ongoing critical debate of the evidence regarding the dose, administration, timing and type of corticosteroids and ongoing randomized controlled trial (RCT) are challenging the recommendation of 6 mg of dexamethasone for all patients with severe form of COVID-19. The dynamic of COVID-19 surges, flip-flop of official recommendations within very short period of time and ongoing critical debate could be with possible variations of daily clinical practice regarding using systemic corticosteroids. In an electronic evaluation form that will be send to European Society of Intensive Care (ESICM) Members. The electronic survey will contain 10 question. In the questionnaire the participants will have to describe their routine clinical practice regarding administration of systemic corticosteroids among patients with COVID-19 ARDS.

Eligibility criteria: Inclusion Criteria:

* Members of European Society of Intensive Care

Exclusion Criteria:

* not members of European Society of Intensive Care

Primary outcomes:
measure: Systemic corticosteroids among patients with COVID-19 ARDS practice - questionnaire (electronic survey)
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Brno
country: Czechia
facility: University Hospital Brno
Study officials:
affiliation: University Hospital Brno
name: Jan Malaska, MD., Ph.D
role: PRINCIPAL_INVESTIGATOR
References: